Emma J. Birks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emma J. Birks has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Mark S. Slaughter
Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky
4 shared publications Andrew Lenneman
3 shared publicationsAmaninderapal S. Ghotra
2 shared publications- Francis D. Pagani
Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan
2 shared publications Zeeshan Hussain
2 shared publicationsAbbas Bitar
1 shared publication
Latest Publications
- 5 September 2020
- Published by Springer Nature
- p. 623-639
Risk Factors for Mechanical Circulatory Support Use and Risk Assessment
- 5 September 2020
- Published by Springer Nature
- p. 623-639
Risk Factors for Mechanical Circulatory Support Use and Risk Assessment
- 29 September 2017
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 121 (8) , 902-904
Stopping LVAD Bleeding
- 29 September 2017
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 121 (8) , 902-904
Stopping LVAD Bleeding
- 1 July 2016
- Published by Elsevier in JACC: Heart Failure
- Vol. 4 (7) , 577-579
The Promise of Recovery ∗
- 1 July 2016
- Published by Elsevier in JACC: Heart Failure
- Vol. 4 (7) , 577-579
The Promise of Recovery ∗
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S93
Impact of Pulmonary Function Tests on Outcomes in Patients after Left Ventricular Assist Device Implantation
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S93
Impact of Pulmonary Function Tests on Outcomes in Patients after Left Ventricular Assist Device Implantation
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S44
Arrhythmic Outcomes in Patients following Explanation of Left Ventricular Assist Devices after Myocardial Recovery
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S44
Arrhythmic Outcomes in Patients following Explanation of Left Ventricular Assist Devices after Myocardial Recovery
- 1 June 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (6) , 815-824
An examination of survival by sex and race in the HeartWare Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) and continued access protocol trials
- 1 June 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (6) , 815-824
An examination of survival by sex and race in the HeartWare Ventricular Assist Device for the Treatment of Advanced Heart Failure (ADVANCE) Bridge to Transplant (BTT) and continued access protocol trials
- 1 August 2014
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 20 (8) , S43-S44
A Single Center Experience in Racial Differences at the Time of Referral To Advanced Heart Failure Clinic
- 1 August 2014
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 20 (8) , S43-S44
A Single Center Experience in Racial Differences at the Time of Referral To Advanced Heart Failure Clinic
- 4 February 2014
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 16 (3) , 1-9
Treatment Strategies for Myocardial Recovery in Heart Failure
Heart failure is a progressive disorder characterized by adverse left ventricular remodeling. Until recently, this has been thought to be an irreversible process. Mechanical unloading with a left ventricular assist device (LVAD), particularly if combined with neurohormonal blockade with heart failure medications, can lead to a reversal of the heart failure phenotype, a process called “reverse remodeling.” Reverse remodeling refers to the regression of pathologic myocardial hypertrophy and improvement in LV chamber size that can occur in response to treatment. Myocardial recovery is the sustained normalization of structural, molecular, and hemodynamic changes sufficient to allow explant of the LVAD. Despite the fact that reverse remodeling is commonly seen in LVAD patients in clinical practice, myocardial recovery sufficient to allow device explantation is still rare. Previous experience suggests that young patients with short duration of heart failure and less myocardial fibrosis may be more likely to recover. Alternatively, it may just be that clinicians make a greater effort to recover these subgroups. A combined approach of mechanical unloading with LVADs and pharmacological management, together with regular testing of underlying myocardial function with the pump reduced to a speed at which it is not contributing, can increase the frequency of sustained recovery from heart failure. The goal is to achieve optimal unloading of the myocardium, combined with pharmacologic therapy aimed at promoting reverse remodeling. Myocardial recovery must be considered as a therapeutic target. Clinical variables such as pump speed and blood pressure must be optimized to promote maximal unloading, leading to reverse remodeling and myocardial recovery. Frequent echocardiographic and hemodynamic evaluation of underlying myocardial function must be performed. The combination of LVAD therapy with optimal neurohormonal blockade appears promising as an approach to myocardial recovery. In addition, there is a growing body of translational research which, when combined with LVADs, may further promote more durable recovery. Strategies to thicken the myocardium to enhance the durability of recovery prior to explantation, such as clenbuterol (which induces “physiological hypertrophy”), or intermittently reducing the pump speed to increase myocardial load may be beneficial. Emergence of cardiac stem cells and alternative biologic agents, when added to current therapies, may have a complementary role in promoting and maintaining myocardial recovery. This review will summarize both current strategies and emerging therapies.
- 4 February 2014
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 16 (3) , 1-9
Treatment Strategies for Myocardial Recovery in Heart Failure
Heart failure is a progressive disorder characterized by adverse left ventricular remodeling. Until recently, this has been thought to be an irreversible process. Mechanical unloading with a left ventricular assist device (LVAD), particularly if combined with neurohormonal blockade with heart failure medications, can lead to a reversal of the heart failure phenotype, a process called “reverse remodeling.” Reverse remodeling refers to the regression of pathologic myocardial hypertrophy and improvement in LV chamber size that can occur in response to treatment. Myocardial recovery is the sustained normalization of structural, molecular, and hemodynamic changes sufficient to allow explant of the LVAD. Despite the fact that reverse remodeling is commonly seen in LVAD patients in clinical practice, myocardial recovery sufficient to allow device explantation is still rare. Previous experience suggests that young patients with short duration of heart failure and less myocardial fibrosis may be more likely to recover. Alternatively, it may just be that clinicians make a greater effort to recover these subgroups. A combined approach of mechanical unloading with LVADs and pharmacological management, together with regular testing of underlying myocardial function with the pump reduced to a speed at which it is not contributing, can increase the frequency of sustained recovery from heart failure. The goal is to achieve optimal unloading of the myocardium, combined with pharmacologic therapy aimed at promoting reverse remodeling. Myocardial recovery must be considered as a therapeutic target. Clinical variables such as pump speed and blood pressure must be optimized to promote maximal unloading, leading to reverse remodeling and myocardial recovery. Frequent echocardiographic and hemodynamic evaluation of underlying myocardial function must be performed. The combination of LVAD therapy with optimal neurohormonal blockade appears promising as an approach to myocardial recovery. In addition, there is a growing body of translational research which, when combined with LVADs, may further promote more durable recovery. Strategies to thicken the myocardium to enhance the durability of recovery prior to explantation, such as clenbuterol (which induces “physiological hypertrophy”), or intermittently reducing the pump speed to increase myocardial load may be beneficial. Emergence of cardiac stem cells and alternative biologic agents, when added to current therapies, may have a complementary role in promoting and maintaining myocardial recovery. This review will summarize both current strategies and emerging therapies.
- Open Access
- 30 August 2013
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 113 (6) , 777-791
Molecular Changes After Left Ventricular Assist Device Support for Heart Failure
Heart failure is associated with remodeling that consists of adverse cellular, structural, and functional changes in the myocardium. Until recently, this was thought to be unidirectional, progressive, and irreversible. However, irreversibility has been shown to be incorrect because complete or partial reversal can occur that can be marked after myocardial unloading with a left ventricular assist device (LVAD). Patients with chronic advanced heart failure can show near-normalization of nearly all structural abnormalities of the myocardium or reverse remodeling after LVAD support. However, reverse remodeling does not always equate with clinical recovery. The molecular changes occurring after LVAD support are reviewed, both those demonstrated with LVAD unloading alone in patients bridged to transplantation and those occurring in the myocardium of patients who have recovered enough myocardial function to have the device removed. Reverse remodeling may be attributable to a reversal of the pathological mechanisms that occur in remodeling or the generation of new pathways. A reduction in cell size occurs after LVAD unloading, which does not necessarily correlate with improved cardiac function. However, some of the changes in both the cardiac myocyte and the matrix after LVAD support are specific to myocardial recovery. In the myocyte, increases in the cytoskeletal proteins and improvements in the Ca 2+ handling pathway seem to be specifically associated with myocardial recovery. Changes in the matrix are complex, but excessive scarring appears to limit the ability for recovery, and the degree of fibrosis in the myocardium at the time of implantation may predict the ability to recover.
- 30 August 2013
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 113 (6) , 777-791
Open AccessMolecular Changes After Left Ventricular Assist Device Support for Heart Failure
Heart failure is associated with remodeling that consists of adverse cellular, structural, and functional changes in the myocardium. Until recently, this was thought to be unidirectional, progressive, and irreversible. However, irreversibility has been shown to be incorrect because complete or partial reversal can occur that can be marked after myocardial unloading with a left ventricular assist device (LVAD). Patients with chronic advanced heart failure can show near-normalization of nearly all structural abnormalities of the myocardium or reverse remodeling after LVAD support. However, reverse remodeling does not always equate with clinical recovery. The molecular changes occurring after LVAD support are reviewed, both those demonstrated with LVAD unloading alone in patients bridged to transplantation and those occurring in the myocardium of patients who have recovered enough myocardial function to have the device removed. Reverse remodeling may be attributable to a reversal of the pathological mechanisms that occur in remodeling or the generation of new pathways. A reduction in cell size occurs after LVAD unloading, which does not necessarily correlate with improved cardiac function. However, some of the changes in both the cardiac myocyte and the matrix after LVAD support are specific to myocardial recovery. In the myocyte, increases in the cytoskeletal proteins and improvements in the Ca 2+ handling pathway seem to be specifically associated with myocardial recovery. Changes in the matrix are complex, but excessive scarring appears to limit the ability for recovery, and the degree of fibrosis in the myocardium at the time of implantation may predict the ability to recover.